Introduction {#Sec1}
============

Childhood and adolescence are crucial times for the development of a healthy skeletal and vascular system; alterations in bone modeling/remodeling or vascular biology in youth carry consequences that severely impact on quality of life as well as life span. In childhood, chronic kidney disease (CKD) causes disordered regulation of mineral metabolism, with subsequent alterations in bone modeling, remodeling, and growth. These alterations occur early in the course of CKD and are accompanied by the development of cardiovascular calcifications. Since growth failure and short stature are clinically apparent and concerning to patients, families, and physicians alike, optimization of growth and final adult height has been a focus of CKD management in children for decades. More recently, however, a growing awareness that cardiovascular calcifications accompany CKD, that cardiovascular disease is the leading cause of mortality in both adults and children with kidney disease, and that therapies designed to treat the skeletal consequences of CKD affect the progression of vascular pathology, has led to a reclassification of the mineral, skeletal, and vascular disease associated with progressive kidney failure. Together, these alterations are termed "CKD mineral and bone disorder" ("CKD-MBD") \[[@CR1]\].

The CKD-MBD is defined as a systemic disorder of mineral and bone metabolism due to CKD that is manifested by either one or a combination of the following: (1) abnormalities of calcium, phosphorus, parathyroid hormone (PTH), or vitamin D metabolism, (2) abnormalities in bone histology, linear growth, or strength, and (3) vascular or other soft tissue calcification. "Renal osteodystrophy" is the specific term used to describe the bone pathology that occurs as a complication of CKD and is, therefore, one aspect of the CKD-MBD. While the definitive evaluation of renal osteodystrophy requires a bone biopsy, this procedure is not routinely performed in the clinical setting. However, bone histomorphometry continues to be the gold standard for the assessment of three essential aspects of bone histology: turnover, mineralization, and volume \[[@CR1]\].

Owing to new concepts and definitions of the mineral and bone alterations associated with CKD, this review outlines the current understanding of abnormal bone and mineral metabolism in CKD and current treatment strategies and their impacts on different aspects of this disorder.

Abnormalities of calcium, phosphorus, PTH, and vitamin D metabolism {#Sec2}
===================================================================

The kidneys regulate intestinal calcium absorption by converting 25-hydroxyvitamin D~3~ \[25(OH)D~3~\], the storage form of vitamin D, to 1,25 dihydroxyvitamin D~3~ \[1,25(OH)~2~ D~3~, calcitriol\], the active form of vitamin D, by means of the enzyme 1 α hydroxylase. Suppression of calcitriol synthesis occurs early in CKD, before alterations in calcium, phosphorus, or PTH levels can be detected \[[@CR2], [@CR3]\]. Low circulating levels of calcitriol are due, in part, to a loss of functioning renal mass and result in decreased intestinal calcium absorption, stimulating a release of PTH \[[@CR4]--[@CR9]\]. In the early stages of CKD, elevated amounts of circulating PTH may result in normal or low serum phosphate levels. In advanced stages, however, decreased glomerular filtration rate limits phosphorus excretion. Hyperphosphatemia ensues, causing further suppression of 1 α hydroxylase activity \[[@CR10]\] and stimulation of PTH release \[[@CR11], [@CR12]\].

As renal function declines, the kidneys and skeleton become increasingly resistant to the actions of PTH, necessitating higher levels of PTH to maintain normal mineral and bone metabolism \[[@CR13]\]. While the primary stimulus for PTH is serum calcium concentration, hyperphosphatemia also potentiates PTH secretion, while vitamin D, acting through the vitamin D receptor in parathyroid gland tissue, suppresses PTH transcription. Over time, chronic hypocalcemia, hyperphosphatemia, and low circulating calcitriol levels result in parathyroid gland hyperplasia \[[@CR14]\]. Since the half-life of parathyroid cells is long---on the order of 30 years---once established, hyperplasia is difficult to reverse. PTH secretion from enlarged parathyroid glands may become uncontrollable, due to the non-suppressible basal activity of a large number of parathyroid cells. Long-term stimulation of parathyroid glands may also lead to chromosomal changes that result in autonomous, unregulated growth and hormone release \[[@CR15]\].

A recently described phosphaturic hormone, fibroblast growth factor 23 (FGF-23), may contribute to the pathogenesis of secondary hyperparathyroidism. FGF-23 was first identified in patients with tumor-induced osteomalacia, autosomal dominant hypophosphatemic rickets, and X-linked hypophosphatemic rickets. In these conditions, elevated circulating levels of FGF-23 result in renal phosphate wasting and suppression of calcitriol production. FGF-23 levels rise as renal failure progresses, with markedly elevated levels present in individuals treated with dialysis \[[@CR16]\]. In the early stages of CKD, increased serum FGF-23 levels are associated with suppression of calcitriol production and may thereby contribute to early stimulation of PTH release \[[@CR17]\].

Abnormalities in bone turnover, mineralization, volume, linear growth, or strength {#Sec3}
==================================================================================

Evaluation of skeletal histology provides both a method for understanding the pathophysiology of renal bone disease and a guide to its proper management. The routine assessment of bone histology is not performed in the clinical setting; however, current recommendations from the National Kidney Foundation \[Kidney Disease Outcomes Quality Initiative (KDOQI) Guidelines\] suggest that a bone biopsy should be considered in all patients with CKD who have fractures with minimal trauma (pathological fractures), suspected aluminum bone disease, or persistent hypercalcemia despite having serum PTH levels between 400 pg/ml and 600 pg/ml (Level of Evidence: Opinion) \[[@CR1], [@CR18]\]. After double tetracycline labeling, bone tissue is obtained from the iliac crest on an outpatient basis with minimal morbidity \[[@CR19], [@CR20]\]. As recently recommended by the Kidney Disease Improving Global Outcomes (KDIGO) workgroup, three areas of bone histology are examined: bone turnover, mineralization and volume, all of which may be altered in patients with CKD \[[@CR1]\].

Bone turnover {#Sec4}
-------------

Traditionally, renal osteodystrophy has been classified primarily on alterations in bone turnover. The primary lesion of renal osteodystrophy in children is one of high bone turnover, also termed "secondary hyperparathyroidism". Long-term exposure to high serum PTH levels often leads to fibrous changes in bones; this lesion is termed "osteitis fibrosa cystica". Since PTH activates the PTH/parathyroid hormone-related protein (PTHrP) receptor on osteocytes and osteoblasts, increasing cellular activity of both osteoblasts and osteoclasts \[[@CR21], [@CR22]\], excessive levels of circulating PTH result in increased bone turnover \[[@CR23]\]. Increased bone turnover (secondary hyperparathyroidism) is evident in patients with early and advanced stages of CKD and is nearly universal in untreated children at the initiation of dialysis \[[@CR24]\]. This condition is marked by increased numbers of osteoblasts and osteoclasts. Due to excess osteoclastic activity, increased resorption of mineral and matrix along trabecular surfaces and haversian canals is evident. Osteitis fibrosa cystica, the advanced lesion of secondary hyperparathyroidism, is also associated with peritrabecular fibrosis \[[@CR25]\].

A state of low-turnover bone disease (adynamic renal osteodystrophy) also occurs in children treated with maintenance dialysis, although it has not been demonstrated in adults or children with earlier stages of CKD \[[@CR26]\]. Adynamic bone results from over-suppression of serum PTH, due to excess treatment with vitamin D and calcium salts and is characterized by normal osteoid volume, an absence of fibrosis, and a reduced bone formation rate, as indicated by reduced or absent double tetracycline label on bone histology \[[@CR27], [@CR28]\]. A paucity of osteoblasts and osteoclasts is present \[[@CR23]\]. Adynamic bone has also been associated with low alkaline phosphatase levels, high serum calcium levels, and a propensity for increased vascular calcification \[[@CR29], [@CR30]\]. In addition to the increased risk of fractures that is observed in adults with adyamic bone, adynamic bone in children treated with dialysis is associated with an increased severity of growth retardation \[[@CR31], [@CR32]\].

Mineralization {#Sec5}
--------------

Alterations in skeletal mineralization are also prevalent in children with CKD \[[@CR33]\]. Increases in unmineralized bone (osteoid), in conjunction with delayed rates of mineral deposition, are common \[[@CR25], [@CR33]\]. Defective mineralization that is associated with high-turnover bone disease is termed "mixed lesion"; when associated with low-to-normal bone turnover, it is referred to as "osteomalacia" \[[@CR1]\]. While the implications of defective mineralization remain to be established, increased fracture rates, bone deformities, and growth retardation are prevalent in patients with CKD and may be due, in part, to altered mineralization.

Volume {#Sec6}
------

Since PTH is an anabolic steroid at the level of trabecular bone, high levels of serum PTH are typically associated with increases in bone volume, trabecular volume, and trabecular width \[[@CR20], [@CR33]--[@CR35]\]. Thus, children with CKD typically have normal or high bone volume as assessed by bone histomorphometry. Those treated with corticosteroids, however, may display loss of bone volume, termed "osteoporosis". The impact of osteoporosis in childhood may not always be immediately apparent; however, sub-optimal peak bone mass accretion in adolescence is associated with an increased risk of osteoporosis, hip fractures, and mortality in adulthood \[[@CR36]\].

Growth {#Sec7}
------

Growth retardation is the hallmark of CKD in children. Protein and calorie malnutrition, metabolic acidosis, end-organ growth hormone resistance, and renal bone disease are the factors most commonly implicated in growth failure \[[@CR37]\]. Despite correction of acidosis and anemia, normalization of serum calcium and phosphorus levels, and vitamin D sterol therapy replacement, the majority of children with CKD continue to grow poorly. Growth failure worsens as renal function declines; the average height of children with even mild CKD \[glomerular filtration rate (GFR) 50--70 ml/min per 1.73 m^2^ body surface area\] is 1 standard deviation score (SDS) below the average for healthy children. Moderate CKD (GFR 25--49 ml/min per 1.73 m^2^) is associated with a height SDS of −1.5, and, at the time of initiation of dialysis, the mean height SDS is −1.8 \[[@CR38]\].

Secondary hyperparathyroidism contributes to growth retardation, although optimal target values for PTH in children in all stages of CKD remain controversial. In children with moderate CKD, some data indicate that normal growth velocity is achieved when PTH levels are maintained within the normal range \[[@CR39]\], while others have demonstrated a linear correlation between growth and PTH levels in the same patient population, those with the highest PTH values maintaining the highest rates of growth \[[@CR40]\]. In children treated with maintenance dialysis, adynamic bone disease and growth failure have been associated with PTH levels around 100 pg/ml (1st generation assay), causing many experts to recommend target PTH levels 3--5 times the normal range in advanced CKD \[[@CR32]\]. Data from the European community, however, have demonstrated that optimal growth velocity in this population may be associated with PTH levels of 2--3 times the normal range \[[@CR41]\]. As a result, optimal PTH targets remain controversial, and recommendations vary between experts (Table [1](#Tab1){ref-type="table"}). Table 1Target PTH ranges by stage of CKDCKD stageGFR range (ml/min per 1.73 m^2^)Target intact PTH (pg/ml)330--59\*35--70‡10--65415--29\*70--110‡10--655\<15 or dialysis\*200--300‡130--195\* recomended by \[[@CR18]\], ‡ recomended by \[[@CR41]\]

Alterations in the growth hormone/insulin-like growth factor (IGF) pathway axis and their receptors also contribute to growth retardation. Despite normal or elevated circulating levels of growth hormone, decreased growth hormone receptor expression results in end-organ resistance. Furthermore, increased levels of IGF binding proteins, in the presence of normal IGF1 levels, result in decreased bioactivity of IGF1 \[[@CR42]--[@CR44]\].

Bone deformities are also common in uremic children, due to altered skeletal remodeling. Epiphyseal widening, particularly around wrists, ankles, and the costochondral junctions (rachitic rosary), is common in infants. Slipped epiphyses, genu valgum, and femoral and wrist deformities are most common in pre-adolescent children with long-standing CKD \[[@CR24], [@CR45]\]. Avascular necrosis of the femoral head and pathologic fractures of the extremities and chest wall due to osteoporosis and bone deformities may occur with minimal trauma. In addition, vertebral crush fractures contribute to significant morbidity in this population. The initial management of skeletal deformities requires the normalization of serum calcium, phosphorus, and PTH levels. Surgical correction is often also necessary but should be performed only after correction of biochemical abnormalities \[[@CR18]\].

Biomarkers of renal osteodystrophy {#Sec8}
==================================

Serum calcium and phosphorus {#Sec9}
----------------------------

Serum calcium and phosphorus levels remain stable in mild-to-moderate stages of CKD. As renal failure advances, however, serum calcium levels drop in response to decreased intestinal calcium absorption resulting from low circulating levels of 1,25(OH)~2~D~3~ \[[@CR2]\]. Treatment with active vitamin D sterols and phosphate binders corrects hypocalcemia, and, in stage 5 CKD, hypercalcemia may develop in response to aggressive treatment with high doses of vitamin D sterols and calcium-based phosphate binders. In this context, increased serum calcium, in conjunction with low levels of PTH and alkaline phosphatase, may signal the development of adynamic bone \[[@CR32]\]. Adjustment of vitamin D dosage and the use of non-calcium-containing phosphate binders can prevent the development of this complication as well as its associated growth failure \[[@CR32]\]. Avoidance of increased serum calcium levels, which are associated with an increased risk of mortality in large populations of adult dialysis patients, also may prevent the progression of cardiovascular calcification (vide infra) \[[@CR46], [@CR47]\].

Similar to those of serum calcium, serum phosphorus levels remain within the normal range until CKD stages 4 to 5 are reached, when decreased GFR limits urinary phosphate excretion. Serum PTH levels rise but fail to compensate for phosphorus retention \[[@CR2]\]. In stage 5 CKD, traditional hemodialysis or peritoneal dialysis typically removes less than half of ingested phosphate, necessitating the use of phosphate binders to control serum phosphorus and PTH levels. Since elevated values for the serum calcium × phosphorus product have been associated with vascular calcification and increased rates of mortality \[[@CR48]--[@CR50]\], maintaining serum calcium and phosphorus levels within the normal range is important for optimizing cardiovascular health in all stages of CKD (vide infra) \[[@CR18]\].

Alkaline phosphatase activity {#Sec10}
-----------------------------

Serum alkaline phosphatase values are fair markers of osteoblastic activity in children with CKD. Osteoblasts normally express large amounts of the bone isoenzyme of alkaline phosphatase, and elevated serum levels correlate with increased bone formation, high levels of serum PTH, and growth hormone therapy \[[@CR51]\]. Since alkaline phosphatase is also present in the liver, elevated serum levels of total alkaline phosphatase may not always indicate increased bone turnover. Measurement of the heat-stabile and heat-labile fractions may help to separate skeletal from hepatic causes of elevated levels. Alkaline phosphatase measurements are useful in monitoring the skeletal response to treatment with vitamin D sterols in patients with osteitis fibrosa; values that decrease over several months usually indicate histologic improvement \[[@CR52]\]. However, consistently low serum alkaline phosphatase values, particularly in children with stage 5 CKD receiving large doses of vitamin D sterols and calcium-containing phosphate binders, are consistent with adynamic bone \[[@CR32]\].

Parathyroid hormone {#Sec11}
-------------------

Serum PTH levels are widely used as non-invasive markers in distinguishing low-turnover lesions from osteitis fibrosa \[[@CR33], [@CR53]\]. Current recommendations for target PTH levels are based on measurements obtained by the 1st generation PTH assay in cross-sectional bone biopsy data from children treated with maintenance dialysis and receiving either low-dose oral calcitriol or no vitamin D sterol therapy. Since the 1st generation assays measure both full-length molecule and amino-terminally truncated fragments, 2nd generation PTH assays have been developed which measure, exclusively, the full-length molecule ("PTH(1--84)"). Although some data suggest improved ability of the newer 2nd generation assays to predict low-turnover bone disease \[[@CR54]\], this finding has not been substantiated by others \[[@CR34], [@CR55]\].

Increasing skeletal resistance to the actions of PTH requires that PTH be maintained at higher levels in advanced stages of CKD \[[@CR56]--[@CR58]\] (Table [1](#Tab1){ref-type="table"}). Downregulation of the PTH receptor, decreased expression of osteoblast differentiation factor, and increased levels of osteoclastogenesis inhibitory factor occur with decreased renal function, contributing to the skeletal resistance to PTH \[[@CR57], [@CR59]\]. In patients with mild to moderate CKD, PTH levels that are within the normal range generally correspond to normal rates of bone formation, while mildly increased levels suggest the presence of secondary hyperparathyroidism \[[@CR26]\]. In patients undergoing maintenance dialysis who are either untreated or are receiving small daily oral doses of calcitriol, PTH(7--84) levels of approximately two to five times the upper limit of normal generally correspond to normal bone formation rates \[[@CR26], [@CR33], [@CR41], [@CR53], [@CR60]\]. Over-suppression of PTH in patients on dialysis has also been shown to result in growth failure, hypercalcemia, and adynamic bone \[[@CR32]\]. In summary, PTH levels should be maintained in the range appropriate to the stage of CKD; levels appropriate for early stages of CKD would indicate low-turnover disease in patients treated with dialysis, while appropriate levels for stage 4 CKD represent osteitis fibrosa in mild CKD.

25(OH) vitamin D {#Sec12}
----------------

Careful attention to 25(OH) vitamin D (native vitamin D) nutrition is also fundamental to the optimal management of renal osteodystrophy \[[@CR18]\]. Native vitamin D deficiency is prevalent in all children, including those with normal renal function \[[@CR61]\], and the presence of renal insufficiency exacerbates this deficiency. Currently, therapeutic native vitamin D is available in two forms: vitamin D~2~ (ergocalciferol) is obtained from plants and vitamin D~3~ (cholecalciferol) is obtained from animal sources. Repletion of vitamin D stores has been shown to increase calcitriol production, ameliorate secondary hyperparathyroidism \[[@CR62], [@CR63]\], and heal lesions of poor mineralization in patients with CKD stages 2 through 4 \[[@CR64]\]. Thus, assessment and repletion of native vitamin D stores are recommended in this population \[[@CR18]\]. Of note, current dosage recommendations for native vitamin D repletion are similar to doses recommended for the treatment of nutritional rickets and far exceed recommendations for routine daily intake (Table [2](#Tab2){ref-type="table"}). Table 2Native vitamin D dosing by degree of D deficiencySerum 25(OH) vitamin D (ng/ml)Ergocalciferol (vitamin D~2~) doseComment\<5 (severe deficiency)8,000 IU/d p.o. × 4 weeks, then 4,000 IU/d × 2 monthsMeasure 25(OH)D level after 3 months5--15 (mild deficiency)4,000 IU/d daily p.o. × 12 weeksMeasure 25(OH)D level after 3 months5--30 (mild deficiency)2,000 IU/d daily p.o. × 12 weeks

FGF-23 {#Sec13}
------

FGF-23 is a newly described phosphaturic hormone associated with renal phosphate wasting \[[@CR65]\], low serum 1,25(OH)~2~D~3~ levels, and osteomalacia in animals and humans with normal kidney function \[[@CR66]--[@CR68]\]. Levels increase as kidney disease progresses and are markedly elevated in patients treated with maintenance dialysis \[[@CR16]\]. Current data indicate that increased levels correlate with calcitriol deficiency in adults with CKD stages 2 to 4 \[[@CR17]\], that dietary phosphorus regulates serum levels of FGF-23 \[[@CR69], [@CR70]\], and that the administration of vitamin D sterols increases levels \[[@CR71]\]. Furthermore, elevated pre-treatment values of serum FGF-23 may predict resistance of the parathyroid glands to therapy with vitamin D sterols \[[@CR72], [@CR73]\]. These findings implicate a role for FGF-23 in the control of serum phosphorus and vitamin D metabolism, as well as in the pathogenesis of secondary hyperparathyroidism.

A schematic representation of the interplay between PTH, FGF-23, and calcitriol is depicted in Fig. [1](#Fig1){ref-type="fig"}. Fig. 1Schematic representation of the interplay between PTH, FGF-23, and calcitriol in mineral metabolism in vivo. *Solid arrows* represent the actions of PTH, while *open arrows* represent those of FGF-23

Vascular or other soft tissue calcification {#Sec14}
===========================================

Extra-skeletal calcification, including vascular calcification, is prevalent in adults treated with dialysis \[[@CR46], [@CR47]\], has its origins in childhood \[[@CR48], [@CR49]\], and is associated with significant cardiovascular morbidity and mortality \[[@CR74], [@CR75]\]. In contrast to the calcifications of atherosclerotic plaques in the vascular intima that develop with age in individuals with normal kidney function, vascular calcification in the uremic milieu develops primarily in the vascular media. Hypercalcemia, hyperphosphatemia, elevated levels of the calcium × phosphorus product, and high doses of vitamin D sterols \[[@CR48]--[@CR50]\] have all been implicated in the progression of the burden of extra-skeletal calcification. However, 40% of adult patients with stage 3 CKD, without these risk factors, show evidence of calcification \[[@CR76]\], suggesting that factors in the uremic milieu itself, apart from high levels of calcium and phosphorus, contribute to cardiovascular disease. Furthermore, increased intimal--medial thickness of the carotid artery is present in both children on dialysis and in those with early stages of CKD \[[@CR77]\], suggesting that vascular abnormality, the leading cause of death in this population, has its origins early in childhood CKD \[[@CR78]\].

Although the mechanisms of the development of vascular calcification remain to be fully elucidated, osteoblasts and vascular smooth muscle cells have a common mesenchymal origin; core binding factor-1 (Cbfa1) is thought to trigger mesenchymal cell to osteoblast transformation. Mice deficient in Cbfa1 fail to mineralize bone \[[@CR79]\], and arteries obtained from patients undergoing renal transplantation show increased levels of the protein \[[@CR80]\]. Upregulation of the sodium-dependent phosphate transporter PIT-1 likely contributes to increased calcification \[[@CR81], [@CR82]\]. Furthermore, upregulation of pro-mineralization factors, such as osteopontin, bone sialoprotein, osteonectin, alkaline phosphatase, type I collagen, and bone morphogenic protein-2 (BMP-2), is potentiated by the uremic milieu \[[@CR83]--[@CR86]\], while expression of calcification inhibitors, such as fetuin A and matrix Gla protein, is suppressed \[[@CR87]--[@CR89]\]. Levels of circulating FGF-23 may also contribute, as values are inversely correlated with peripheral vascular calcification in adult dialysis patients \[[@CR90]\]. Treatment with high doses of calcium salts, in the form of calcium-based phosphate binders, has also been implicated in the progression of cardiovascular calcification in adult patients treated with maintenance dialysis, and this progression is prevented with the use of non-calcium-containing phosphate binders \[[@CR46], [@CR47]\].

Treatment {#Sec15}
=========

The goal of therapy in childhood CKD-MBD is to normalize mineral metabolism with the aim of improving growth and reducing bone deformities and fragility, while minimizing the progression of extra-skeletal calcification. Biochemical markers of serum calcium, phosphorus, and PTH are primarily used to guide therapy; current therapeutic agents are targeted to maintain values in the normal range for the stage of CKD (Table [1](#Tab1){ref-type="table"}).

Phosphorus control {#Sec16}
------------------

As a result of phosphorus retention in CKD stages 4 and 5 \[[@CR91]\], patients with advanced CKD and those undergoing treatment with traditional maintenance dialysis regimens---thrice-weekly hemodialysis or nightly peritoneal dialysis---often require dietary phosphate restriction as well as treatment with phosphate-binding agents. Serum phosphorus levels should be maintained within the appropriate range for age and, due to increased rates of growth, infants and young children must maintain higher levels of serum phosphorus than older children. Calcium-containing salts have been recommended as the mainstay in phosphorus binding therapy in CKD stages 3 through 5. While several calcium salts are widely used, including calcium carbonate, calcium acetate, and calcium citrate, calcium carbonate is currently the most commonly used compound \[[@CR27], [@CR92], [@CR93]\]. In recent years, however, increasing concern about the progressive vascular calcifications associated with a positive calcium balance and hypercalcemia has led to the development of non-calcium-containing phosphate binders. Current recommendations suggest that total calcium intake from calcium-based phosphate binders should not exceed twice the recommended daily recommended intake (DRI) for dietary calcium. Elevated serum calcium levels (greater than 10.2 mg/dl) should be treated by the withdrawal of calcium-based phosphate binder therapy and, if persistent, by the discontinuation of active vitamin D sterols \[[@CR18]\].

To avoid excess calcium intake, a metal-free calcium-free phosphate binder, sevelamer hydrochloride (sevelamer HCl, RenaGel) was developed. Although sevelamer is not yet approved for use in children, it has been shown in prospective trials to lower serum phosphorus levels effectively and control the skeletal lesions of secondary hyperparathyroidism without increasing serum calcium levels in children treated with dialysis \[[@CR35], [@CR46], [@CR47], [@CR94]--[@CR96]\]. Use of sevelamer HCl has also been shown to halt the progression of vascular calcification in patients on dialysis, in contrast to the worsening cardiovascular disease associated with long-term calcium-based binder therapy \[[@CR47], [@CR94]\]. Lower mortality rates have also been associated with the use of sevelamer over calcium \[[@CR97]\].

Lanthanum carbonate is a non-calcium-containing, but metal-containing (lanthanum), phosphorus binding agent. Several studies have demonstrated that lanthanum carbonate effectively reduces serum phosphorous levels, and there are fewer hypercalcemic episodes than with calcium carbonate \[[@CR98]--[@CR100]\]. However, plasma lanthanum levels increase over time. Although levels return to baseline after withdrawal of the drug, bone lanthanum content increases during therapy and remains elevated at least a year after discontinuation of treatment \[[@CR101]\]. Further evidence from experiments on rodents indicates progressive liver, bone, and growth plate accumulation \[[@CR102]\]. Thus, although lanthanum carbonate is an effective phosphate binder, long-term therapy results in its accumulation in a number of tissues, the long term consequences of which have yet to be defined \[[@CR103]\].

In select patient populations and dialysis centers which are able to perform daily hemodialysis, the use of phosphate binding medications may be decreased or entirely avoided. Daily hemodialysis has been demonstrated to normalize serum phosphate levels in these patients, leading to improved nutrition, improved growth, and decreased phosphate binder usage \[[@CR104], [@CR105]\].

Secondary hyperparathyroidism {#Sec17}
-----------------------------

25(OH) vitamin D deficiency is common in children with CKD, and assessment and repletion is recommended for all children in stages 2 to 4 CKD with secondary hyperparathyroidism. After repletion of native vitamin D stores, therapy with active vitamin D sterols is effective in suppressing PTH levels to the target range for the stage of CKD. Vitamin D sterols suppress PTH levels by two mechanisms: indirectly, through increased intestinal calcium absorption, and directly, via suppression of PTH gene transcription. Calcitriol and alfacalcidol are widely used in children, have been shown to be effective in suppressing PTH when given in daily or intermittent doses, and improve growth in children with CKD \[[@CR39], [@CR40]\]. However, hypercalcemia has been linked to their administration, particularly when given with calcium-containing phosphate binders. Thus, newer vitamin D analogues have been developed to maximize affinity for parathyroid tissue, while minimizing effects on intestinal calcium and phosphorus absorption. Three new vitamin D analogues are available for use in patients with CKD: 22-oxacalcitriol (OCT) in Japan, as well as 19-nor-1,25-dihydroxyvitamin D~2~ (paricalcitol) and 1α-hydroxyvitamin D~2~ (doxercalciferol) in the USA. Oral forms of paricalcitol and doxercalciferol have been approved for CKD 3 through 5 in adults, though not yet in children. Doxercalciferol and paricalcitol are effective in lowering PTH levels and may have a lower calcemic potential than calcitriol in both adults and children with CKD \[[@CR35], [@CR106]\].

Calcimimetic agents, which act as allosteric activators of the calcium sensing receptor (CaSR), are also available for the treatment of secondary hyperparathyroidism in the adult dialysis population. By increasing the sensitivity of the CaSR, these small organic molecules are able to reduce PTH levels, decrease the calcium--phosphorus product, and may provide a medical means of halting the progression of parathyroid gland hyperplasia \[[@CR107]\]. Cinacalcet has been shown to be effective in the control of secondary hyperparathyroidism in adults with CKD \[[@CR108]\], in those treated with maintenance dialysis \[[@CR109]--[@CR112]\], and in those with functioning renal allografts \[[@CR113]\]. These agents have not been approved for use in children, and, due to the presence of the CaSR on the growth plate \[[@CR114]\], studies are required to confirm their safety and efficacy in young patients.

Growth {#Sec18}
------

Despite correction of acidosis and optimization of nutrition, many children with CKD continue to grow poorly. Recombinant growth hormone therapy may be indicated in those whose height is below the 5th percentile for age and who have open epiphyseal plates. Skeletal X-rays to evaluate bone age are indicated prior to initiation of hormone therapy. Skeletal deformities, such as active rickets or slipped capital femoral epiphyses, should be allowed to heal prior to initiation of therapy. Furthermore, since growth hormone therapy may worsen secondary hyperparathyroidism, serum PTH levels must be well controlled prior to start of therapy and should be routinely monitored during treatment. Of note, the clinical response to recombinant growth hormone differs according to stage of CKD, children with stage 5 CKD displaying a less robust growth response than those with less severe kidney disease \[[@CR115], [@CR116]\]. Thus, many factors, including growth potential, degree of kidney failure, optimal dialysis prescription \[[@CR105]\], concomitant morbidities, and control of renal osteodystrophy, should be considered prior to the initiation of growth hormone therapy.

Vascular disease {#Sec19}
----------------

Since cardiovascular disease is the leading cause of death in both adults and children with CKD, the prevention of cardiovascular disease progression is crucial in the management of the CKD-MBD. The etiology of vascular disease in CKD is multifactorial and includes traditional risk factors, such as hyperlipidemia, hypertension, and inflammation, as well as alterations in mineral metabolism specific to CKD; thus, treatment is also multifaceted. Lipid lowering agents are effective in reducing cardiac mortality in adults with CKD \[[@CR117]\] and in those with stable renal allografts \[[@CR118]\], although no benefit from their use has been established in patients treated with maintenance dialysis \[[@CR119]\]. Normalization of mineral metabolism, by the avoidance of PTH over-suppression, avoidance of hypercalcemia, and the maintenance of normal serum phosphorus and the overall calcium × phosphorus product, is essential in all patients with CKD \[[@CR18]\]. The limiting of total calcium intake to less than twice the DRI for age, in conjunction with the routine monitoring of biochemical parameters and adjustment of both phosphate binder and vitamin D sterol therapy, is recommended to prevent progressive vascular disease. Evaluation of vascular calcifications in children may be performed by ultrasound of carotid intimal--medial wall thickness \[[@CR120]\]. The methodology for coronary electron beam computed tomography (EBCT) and the value of echocardiogram or abdominal X-rays \[[@CR121]\], useful in the adult population, have not been well established in children.

A 12-year-old boy has come to a pediatrician's office for a school physical. He wakes up several times at night to urinate. On examination, he is found to be a pale boy with a height and a weight that are both below the third percentile. He has Tanner 1 pubertal development and normal blood pressure. Serum electrolyte concentrations are: sodium 136 mmol/l, potassium 3.8 mmol/l, chloride 108 mmol/l, total CO~2~ 18 mmol/l, blood urea nitrogen (BUN) 40 mg/dl, creatinine of 1.8 mg/dl (stage 3 CKD), phosphorus 4 mg/dl, calcium 9.9 mg/dl, PTH 170 pg/ml, and a hematocrit of 28%. An appropriate serum PTH level for this child with this degree of renal insufficiency is: 10--65 pg/ml65--110 pg/ml200--300 pg/ml\>400 pg/mlAppropriate management of his secondary hyperparathyroidism does *not* include: measurement and repletion of 25(OH) vitamin Dinitiation of a calcium-free phosphate binderdietary phosphate restrictioninitiation of calcitriol therapyGrowth hormone therapy should be initiated: immediately, to maximize final height potentialafter correction of acidosis, anemia, and secondary hyperparathyroidismafter the initiation of dialysisafter successful renal transplantationgrowth hormone therapy is contraindicated in this childAn 8-year-old girl presents with reflux nephropathy and growth failure and has the following serum biochemical determinations: serum creatinine 2.5 mg/dl (CKD stage 4), calcium 8.9 mg/dl, phosphorus 6 mg/dl, and PTH 140 pg/ml. The first step in serum phosphorus management is: initiation of a non-calcium-containing phosphate bindernutritional assessment and phosphate restrictionvitamin D sterol therapygrowth hormone therapyA 14-year-old boy with obstructive uropathy and stage 3 CKD has been treated with growth hormone therapy for the past 2 years. His growth velocity has been decreasing over the past 6 months. An indication to stop therapy would be: serum PTH level of 150 pg/mlheight at 50% for ageTanner 2 pubertal developmentincreasing alkaline phosphatase activityA 10-year-old boy receiving maintenance hemodialysis is treated with calcium carbonate and thrice-weekly calcitriol to control his renal osteodystrophy. His serum PTH level is 700 pg/ml, phosphorus 5 mg/dl and calcium is 11.5 mg/dl. To ameliorate his hypercalcemia, the next step in his therapy should include: dietary calcium restrictionbone biopsyswitching to a non-calcium-containing phosphate binderincreasing the calcitriol therapyAn 8-year-old girl with reflux nephropathy has stage 3 CKD and a height SD less than the 3rd percentile. Contraindication to starting GH therapy in this patient is: serum PTH level of 900 pg/mlbone age of 6 yearsweight SD at the 3rd percentilerecurrent urinary tract infectionsA 9-year-old boy on dialysis has a serum calcium level of 10.2 mg/dl and serum phosphorus of 7 mg/dl. He currently receives two tablets of calcium carbonate (500 mg) with each meal and snack (a total of eight tablets per day). Optimal control of his serum phosphorus could best be obtained by: dietary protein restriction to 0.8 mg/kg per dayincreasing his calcium carbonate to three tablets with meals and snacksadding sevelamer to his phosphate binder regimenincreasing vitamin D sterol therapystarting him on a calcimimeticA 14-year-old boy with stage 4 CKD has the following serum biochemical determinations: phosphorus 5.8 mg/dl, calcium 9 mg/dl, and PTH 160 pg/ml. The following intervention is *not* recommended at this stage of his treatment: calcium carbonate with mealslanthanum carbonate with mealslow-dose calcitriol, nightlydietary phosphate restriction

**Answers**

1\. a (10--65 pg/ml)

2\. b (initiate calcium-free phosphate binder)

3\. b (after correction of acidosis, anemia and secondary hyperparathyroidism)

4\. b (nutritional assessment and phosphate restriction)

5\. b (height 50% for age)

6\. c (switching to non-calcium phosphate binder)

7\. a (serum PTH 900 pg/ml)

8\. c (add sevelamer)

9\. b (lanthanum carbonate)
